Document is current
Any future updates will be listed below
-
Authors
Das, Shreyasee
Goossens, Julie
Jacobs, Dirk
Dewit, Nele
Pijnenburg, Yolande A. L.
In ‘t Veld, Sjors G. J. G.
Teunissen, Charlotte E.
Vanmechelen, Eugeen
-
Funding
Funding for this research was provided by:
H2020 European Institute of Innovation and Technology (860197)
H2020 European Institute of Innovation and Technology (860197)
H2020 European Institute of Innovation and Technology (18HLT09)
H2020 European Institute of Innovation and Technology (860197)
H2020 European Institute of Innovation and Technology (860197)
- License Information
-
More Information
Article History
Received: 12 November 2022
Accepted: 14 March 2023
First Online: 24 March 2023
Declarations
:
: All animal experiments were performed in accordance with the ARRIVE guidelines, following good laboratory practices and ethical regulations. All clinical CSF samples were procured as a part of the Amsterdam Dementia Cohort Biobank agreement.
: Not applicable.
: S.D., J.G., and D.J. are employees of ADx NeuroSciences, Gent, Belgium. S.D. is also enrolled as a Ph.D. candidate at the Amsterdam University Medical Centre, Amsterdam, Netherlands. E.V.M. is the co-founder of ADx NeuroSciences. C.T. has a collaboration contract with ADx NeuroSciences, Quanterix, and Eli Lilly and has performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is the editor of a Neuromethods book Springer. All the other authors declare no competing interests.
